17,261 trials
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants
HER2 Positive Breast Carcinoma · Stage IV Breast Cancer AJCC v6 and v7
Primary: Percent of Participants With Grade 2 or Higher Toxicities — 80 percentage of participants
Metastatic Breast Cancer · Hormone Receptor Positive
Primary: Percentage of Participants With Grade 3 or 4 Neutropenia — 19.4; 20.5 percentage of participants
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Parkinson's Disease
Primary: Change in Daily "OFF" Time — -2.8; -1.3 Hours
End Stage Renal Disease · Thrombosis
Primary: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0; 0…
Neurofibromatosis 1
Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS) — 0; 3 score on a scale
Breast Cancer
Primary: Objective Response Rate — 50.0; 22.2 percentage of participants
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale
Inflammation Corneal · Pain, Postoperative
Primary: Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0') — 26; 34; 10 participants
Systemic Lupus Erythematosus
Primary: Phase 1b: Number of Participants With Adverse Events (AEs) — 4; 2; 7; 8 Participants
Seborrheic Dermatitis
Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009
Non-Small Cell Lung Cancer
Primary: The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) — 3; 0 Participants
Hidradenitis Suppurativa
Primary: Number of Participants With Adverse Events — 21; 16 Participants
Pain Management
Primary: Pain Reduction at 60 Minutes (Baseline Pain Score - Pain Score at 60 Minutes) — 3.95; 3.95 units on a scale